Drug data last refreshed 16h ago · AI intelligence enriched 3w ago
PENTOTHAL (thiopental sodium) is a barbiturate administered as a rectal suspension, approved in 1959 for use as a sedative-hypnotic agent. The exact current indications are not specified in available data, but historically barbiturates were used for anesthesia induction, seizure control, and sedation. This is a legacy small-molecule product nearing loss of exclusivity.
Declining commercial footprint with minimal linked job openings suggests a small, legacy-focused team likely managing phase-out or maintenance mode operations.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Working on PENTOTHAL offers minimal career growth opportunity, as the product is in late-stage lifecycle with zero linked job openings and no active development pipeline. This role would suit professionals managing legacy products or transitioning toward end-of-life brand stewardship rather than those seeking advancement.
Worked on PENTOTHAL at Abbott? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.